Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 9Depression 9Anxiety Disorders 7Neoplasm Metastasis 3Melanoma 2Depressive Disorder, Major 2Wounds and Injuries 1Trauma, Nervous System 1Stress Disorders, Post-Traumatic 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Osteosarcoma 1Opioid-Related Disorders 1Lymphoma 1Hospice 1Hematopoietic and Lymphatic System Neoplasm 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Endocrine Gland Neoplasms 1Depressive Disorder 1Caregiver Distress 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1Agnosia 1

Interventions

Escitalopram 3Psilocybin 2Interpersonal Psychotherapy 2Infliximab 2Antidepressive Agents 2abacavir 1Venlafaxine Hydrochloride 1Sugars 1Saline Solution 1Mirtazapine 1Ketamine 1Fatty Acids, Omega-3 1Desvenlafaxine Succinate 1Cognitive Behavioral Therapy 1Citalopram 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Depressive Disorder, Major × Psilocybin × Clear all
NCT05947383 2026-05-06

2Dose

Sunstone Medical

Phase 2 Active not recruiting
56 enrolled

Depression, Depressive Disorder, Major, Neoplasms

NCT04593563 2021-10-15

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

Maryland Oncology Hematology, PA

Phase 2 Unknown
30 enrolled

Depressive Disorder, Major, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡